Phathom Pharmaceuticals Inc’s filing revealed that its Director Parikh Asit acquired Company’s shares for reported $44200.0 on Mar 13 ’25. In the deal valued at $4.42 per share,10,000 shares were bought. As a result of this transaction, Parikh Asit now holds 85,500 shares worth roughly $0.47 million.
Then, Henderson Molly sold 6,583 shares, generating $43,371 in total proceeds. Upon selling the shares at $6.59, the CFO and CBO now owns 93,546 shares.
Before that, Nabulsi Azmi sold 7,886 shares. Phathom Pharmaceuticals Inc shares valued at $51,957 were divested by the Chief Operating Officer at a price of $6.59 per share. As a result of the transaction, Nabulsi Azmi now holds 233,390 shares, worth roughly $1.29 million.
Cantor Fitzgerald initiated its Phathom Pharmaceuticals Inc [PHAT] rating to an Overweight in a research note published on February 14, 2025; the price target was $23. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in early May with a ‘”a Buy”‘ rating. Needham also remained covering PHAT and reiterated its “Buy” recommendation on January 05, 2024. H.C. Wainwright started covering the stock on August 09, 2023. It rated PHAT as “a Buy”.
Price Performance Review of PHAT
On Tuesday, Phathom Pharmaceuticals Inc [NASDAQ:PHAT] saw its stock jump 14.46% to $5.54. Over the last five days, the stock has gained 15.66%. Phathom Pharmaceuticals Inc shares have fallen nearly -31.77% since the year began. Nevertheless, the stocks have fallen -28.70% over the past one year. While a 52-week high of $19.71 was reached on 01/02/25, a 52-week low of $4.07 was recorded on 03/14/25. SMA at 50 days reached $5.99, while 200 days put it at $11.09.
Levels Of Support And Resistance For PHAT Stock
The 24-hour chart illustrates a support level at 5.06, which if violated will result in even more drops to 4.59. On the upside, there is a resistance level at 5.93. A further resistance level may holdings at 6.33. The Relative Strength Index (RSI) on the 14-day chart is 51.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 49.48%. Stochastics %K at 29.55% indicates the stock is a holding.
How much short interest is there in Phathom Pharmaceuticals Inc?
A steep rise in short interest was recorded in Phathom Pharmaceuticals Inc stocks on 2025-02-28, dropping by -0.71 million shares to a total of 13.92 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 14.63 million shares. There was a decline of -5.08%, which implies that there is a negative sentiment for the stock.
